Elan Inactive 20-F2012 FY Annual report (foreign)

Filed: 12 Feb 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: AAIC, AAN, Academy, Acino, adhesion, adjunctive, admitted, againstTysabrior, aid, allTysabri, allTysabriIP, allTysabri®intellectual, Ambiorix, announcedTysabri, APIC, asTysabri, aTysabri, aTysabriMaterial, automatically, avoid, BA, Bairu, Banyan, Basi, Beaumont, Biochemistry, Biopharma, biopharmaceutical, BNY, bona, Boulevard, BPD, broaden, burden, caliber, cardiovascular, cell, Chemistry, CHF, Chicago, circumstance, clarity, closesTysabri, commentary, Commerce, compel, confidence, considerTysabri, constraint, consummated, consummation, COO, correlate, CTAD, deferTysabrirevenue, demerger, depression, depressive, deprived, diagnosed, diminution, diverted, DOJ, dramatic, eleven, energy, enjoining, exceptionally, excessive, expectedTysabri, extramural, factual, faith, familiar, fatigue, fellowship, fide, fine, foreseeable, forTysabrior, futureTysabri, gender, Genentech, Guriq, Healthymagination, HSR, impactTysabrirevenue, improvedTysabri, incremental, inflection, inTysabriin, IP, landlord, lifetime, lose, MA, Magnetic, Manhattan, mania, manic, manufacturesTysabri, marketingTysabri, Melinda, metastatic, mood, morbidity, Motor, neurobiology, neuroimaging, Neuron, nonappealable, nonprofit, NPS, ofTysabrithrough, Ohio, OncoCyte, Osama, ourTysabri, ourTysabriIP, ourTysabrirevenue, Park, passion, path, PCAOB, percent, PFIC, postdoctoral, predecessor, prescribeTysabrior, prevalence, Prothena, prudent, reassessment, recalculated, recovered, recurrent, Registrar, repay, rescission, Resonance, reward, satisfaction, sellingTysabrior, Sheahan, signaling, Spanish, specialist, specie, sponsoredTysabri, subscribed, suffer, suicide, superseded, symptomatic, synaptic, taxpayer, TC, temporarily, thereunder, theTysabriTransaction, toTysabrifor, toTysabriIP, Triangle, Tysabrigenerally, underwriter, upfront, useTysabri, usingTysabriand, utilizingTysabri, Vancouver, vii, waiting, waiver, Western, whereTysabri

Removed: abnormal, academic, accumulation, administrator, advancement, aggregation, alter, Amarin, Amgen, amortize, ANDA, APP, ASU, behavioral, bind, Biovail, cap, cascade, Cebix, characteristic, claiming, cleave, client, clinic, clip, commencing, commercializeTysabri, complementary, concept, controlling, convertible, coordinated, debited, dedicated, degenerating, deliver, deposition, designing, desperately, devising, disregarded, distinct, distribute, education, element, employed, enrollment, expedited, experimental, experimenting, exploring, extending, familial, fibrilisation, forecast, formation, forTysabrifor, Frick, fundamental, gained, generation, genetically, genotype, geographic, Georgia, Gothenburg, hallmark, Icarom, impracticable, indirect, initiate, insoluble, InterMune, intravenously, introduced, inTysabrifor, invention, John, Judicial, labor, leading, leasehold, licensee, linked, lost, marketingTysabriin, Minnesota, misfolded, movement, Multidistrict, neurodegeneration, neuroprotective, ofTysabriat, ofTysabrithat, owed, Panel, parkin, participated, pathology, pathway, peptide, pertaining, Pharmacia, physical, piece, plaque, postponement, precursor, prescribe, produce, prompting, proportional, pursue, pursued, Readymix, reclassified, regulated, remedy, remittance, reversing, Schwarz, selectively, shifting, Skelaxin, Sofinnova, stipulated, stockbroking, studied, substantive, surgeon, Sweden, theNew, tissue, today, traditional, transitioned, treating, TriCor, unavoidable, undelivered, unmet, Usama, validated, violated, waive, Warburg, Watson

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Elan similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 13.1

Certification Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report on Form 20-F for the period ending December 31, 2012 (the “Report”) of Elan Corporation, plc (the Company), as filed with the Securities and Exchange Commission on the date hereof, I, G. Kelly Martin, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

This certification accompanies this Report pursuant to section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

/s/ G. KELLY MARTIN

G. Kelly Martin

Chief Executive Officer

Date: February 12, 2013